Univariate analysis of prognostic factors and plasma EBV-DNA in terms of OS and PFS rates
| . | 3-y OS (%) . | P . | 3-y PFS (%) . | P . |
|---|---|---|---|---|
| Age, y | .940 | .904 | ||
| ≤ 60 | 82.6 | 66.7 | ||
| > 60 | 83.3 | 62.5 | ||
| Sex | .387 | .869 | ||
| Male | 85.4 | 65.0 | ||
| Female | 77.0 | 69.3 | ||
| B-symptoms | .995 | .436 | ||
| Presence | 82.6 | 59.6 | ||
| Absence | 83.0 | 70.4 | ||
| Primary site | .870 | .649 | ||
| Nasal cavity | 83.6 | 68.5 | ||
| Others | 74.1 | 49.2 | ||
| LDH level | .290 | .930 | ||
| Elevated | 0.713 | 65.4 | ||
| Normal | 0.855 | 66.4 | ||
| Ann Arbor stage | .020 | .069 | ||
| I | 87.1 | 69.5 | ||
| II | 57.7 | 48.5 | ||
| ECOG score | .202 | .129 | ||
| 0 | 76.0 | 55.8 | ||
| 1 | 88.2 | 77.0 | ||
| IPI | .813 | .430 | ||
| 0 | 81.8 | 63.7 | ||
| 1-2 | 84.0 | 73.0 | ||
| Pretreatment | .002 | .045 | ||
| ≤ 500 copies/mL | 97.1 | 79.0 | ||
| > 500 copies/mL | 66.3 | 52.2 | ||
| After treatment | .031 | .028 | ||
| Undetectable | 92.0 | 77.5 | ||
| Detectable | 69.8 | 50.7 |
| . | 3-y OS (%) . | P . | 3-y PFS (%) . | P . |
|---|---|---|---|---|
| Age, y | .940 | .904 | ||
| ≤ 60 | 82.6 | 66.7 | ||
| > 60 | 83.3 | 62.5 | ||
| Sex | .387 | .869 | ||
| Male | 85.4 | 65.0 | ||
| Female | 77.0 | 69.3 | ||
| B-symptoms | .995 | .436 | ||
| Presence | 82.6 | 59.6 | ||
| Absence | 83.0 | 70.4 | ||
| Primary site | .870 | .649 | ||
| Nasal cavity | 83.6 | 68.5 | ||
| Others | 74.1 | 49.2 | ||
| LDH level | .290 | .930 | ||
| Elevated | 0.713 | 65.4 | ||
| Normal | 0.855 | 66.4 | ||
| Ann Arbor stage | .020 | .069 | ||
| I | 87.1 | 69.5 | ||
| II | 57.7 | 48.5 | ||
| ECOG score | .202 | .129 | ||
| 0 | 76.0 | 55.8 | ||
| 1 | 88.2 | 77.0 | ||
| IPI | .813 | .430 | ||
| 0 | 81.8 | 63.7 | ||
| 1-2 | 84.0 | 73.0 | ||
| Pretreatment | .002 | .045 | ||
| ≤ 500 copies/mL | 97.1 | 79.0 | ||
| > 500 copies/mL | 66.3 | 52.2 | ||
| After treatment | .031 | .028 | ||
| Undetectable | 92.0 | 77.5 | ||
| Detectable | 69.8 | 50.7 |